Science and Technology Production
Article
Authorship
Grotz, Estefanía
;
TATEOSIAN, NANCY LILIANA
;
Salgueiro, María Jimena
;
BERNABEU, EZEQUIEL ADRIAN
;
Gonzalez, Lorena
;
Manca, Maria Letizia
;
AMIANO, NICOLAS OSCAR
;
Valenti, Donatella
;
Manconi, Maria
;
GARCIA, VERONICA EDITH
;
MORETTON, MARCELA ANALIA
;
CHIAPPETTA, DIEGO ANDRES
Date
2019
Publishing House and Editing Place
EDITIONS SANTE
Magazine
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,
vol. 53
(pp. 1-10)
EDITIONS SANTE
Summary
Information provided by the agent in
SIGEVA
Tuberculosis (TB) stands as the second “most deadly infectious disease” behind AIDS. Rifampicin (RIF) represents one of the most effective anti-TB drugs of the “short-term” oral TB therapy. However, the main limitations of the oral treatment are related with the lack of patient adherence and the development of multi-drug resistant Mycobacterium tuberculosis (Mtb) strains. Recently, the pulmonary administration of anti-TB drugs has become an attractive alternative to impr...
Tuberculosis (TB) stands as the second “most deadly infectious disease” behind AIDS. Rifampicin (RIF) represents one of the most effective anti-TB drugs of the “short-term” oral TB therapy. However, the main limitations of the oral treatment are related with the lack of patient adherence and the development of multi-drug resistant Mycobacterium tuberculosis (Mtb) strains. Recently, the pulmonary administration of anti-TB drugs has become an attractive alternative to improve TB therapy. Hence, we have developed a respirable nanocarrier based on RIF-loaded polymeric micelles (PMs), employing a commercially available graft-copolymer of poly (vinyl caprolactam)-poly (vinyl acetate)-poly (ethylene glycol) (Soluplus). The RIF apparent aqueous solubility was increased (14.3-fold) and the micellar system was ranged in the nanoscale (~107 nm). Then, according to its in vitro aerodynamic behavior, our nanoformulation represented a suitable system for deep lung drug delivery. Interestingly, these inhalable RIF-loaded PMs enhanced (up to 2.5-fold) the in vitro drug microbicidal activity in Mtb-infected THP-1 macrophages versus a RIF solution. In addition, the biodistribution studies of the radiolabelled (99mTc) PMs demonstrated their lung accumulation over 24 hs in rats. Overall, this novel nanoformulation stands as an attractive platform for a potential inhalable TB therapy.
Show more
Show less
Key Words
MYCOBACTERIUM TUBERCULOSISSOLUPLUSRIFAMPICINRESPIRABLE NANOCARRIERSPOLYMERIC MICELLESTUBERCULOSIS
Download or request the full text